Literature DB >> 21629286

Ipilimumab.

Vernon K Sondak, Keiran S M Smalley, Ragini Kudchadkar, Seden Grippon, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21629286     DOI： 10.1038/nrd3463

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Cytotoxic T-lymphocyte-associated antigen-4.

Authors:  April K S Salama; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2011-04-05       Impact factor: 12.531

5.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

6.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

Review 7.  Systematic review of medical treatment in melanoma: current status and future prospects.

Authors:  Claus Garbe; Thomas K Eigentler; Ulrich Keilholz; Axel Hauschild; John M Kirkwood
Journal:  Oncologist       Date:  2011-01-06

8.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779
  8 in total
  45 in total

Review 1.  A brief history of melanoma: from mummies to mutations.

Authors:  Vito W Rebecca; Vernon K Sondak; Keiran S M Smalley
Journal:  Melanoma Res       Date:  2012-04       Impact factor: 3.599

Review 2.  Building better monoclonal antibody-based therapeutics.

Authors:  George J Weiner
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

3.  Novel immune checkpoint blocker approved for the treatment of advanced melanoma.

Authors:  Lorenzo Galluzzi; Guido Kroemer; Alexander Eggermont
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

4.  Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

Authors:  Chris Fellner
Journal:  P T       Date:  2012-09

5.  Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.

Authors:  Hongyan He; Xiyan Nan; Shuang Liu; Liangren Zhang; Zhenjun Yang; Yun Wu; Lihe Zhang
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

6.  Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series.

Authors:  Le Min; Anand Vaidya; Carolyn Becker
Journal:  Endocr Pract       Date:  2012 May-Jun       Impact factor: 3.443

7.  CTLA4Ig inhibits effector T cells through regulatory T cells and TGF-β.

Authors:  Christine M Deppong; Traci L Bricker; Brandy D Rannals; Nico Van Rooijen; Chyi-Song Hsieh; Jonathan M Green
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

Review 8.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Aurélien Marabelle; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

9.  Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.

Authors:  Kristian M Koller; Heath B Mackley; Jason Liu; Henry Wagner; Giampaolo Talamo; Todd D Schell; Colette Pameijer; Rogerio I Neves; Bryan Anderson; Kathleen M Kokolus; Carol A Mallon; Joseph J Drabick
Journal:  Cancer Biol Ther       Date:  2016-12-01       Impact factor: 4.742

Review 10.  Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity.

Authors:  Maryann E Mikucki; Daniel T Fisher; Amy W Ku; Michelle M Appenheimer; Jason B Muhitch; Sharon S Evans
Journal:  Int J Hyperthermia       Date:  2013-07-17       Impact factor: 3.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.